1. Introduction
prostate cancer, non-metastatic
PROSTATE CANCER, SOLID TUMOR
These authors contributed equally to this work.These authors contributed equally to this work.The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSolGlobally, prostate cancer is the second most common solid tumor [Thus, there is a need to evaluate new non-toxic therapies for BRPC-M0 [PectaSolIn clinical trials evaluating new compounds in BRPC-MO, common endpoints include PSA dynamics as reflected by the PSADT [In previous clinical trials in BRPC-MO, P-MCP therapy was associated with a positive effect on prostate-specific antigen (PSA) dynamics, including a decrease in PSA level and lengthening of PSADT in a significant proportion of patients, [